



SYRMA SGS

Consumer Durables

09 February 2023

Nilesh Patil | Vinod Chari

**Tanay Rasal** 

research@bobcaps.in

## Strong topline but margins soften

- Q3 topline growth robust at 70% YoY led by resilient domestic demand; order book expands further to Rs 21bn
- EBITDA margin down 300bps YoY to 9.3% on higher RM cost and weakness in exports & healthcare business
- We revise FY23/FY24 EPS by +7%/-3%; on rollover, our TP moves to Rs 400 (from Rs 390) – retain BUY

**Q3 ahead of estimates:** Syrma beat our Q3FY23 estimates as resilient domestic demand more than compensated for weakness in exports. The topline increased 70% YoY to Rs 5.1bn (Rs 4.1bn est.) as the auto/consumer electricals & appliances segments continued to witness strong traction, growing 70%/3x YoY. This offset a 76% YoY contraction in the healthcare segment amidst inflationary pressures in overseas markets, especially Europe. A stronger topline coupled with higher other income aided Q3 net profit of Rs 332mn (Rs 233mn est.), up 68% YoY.

**Margins moderate:** A doubling of raw material cost YoY dragged the gross margin down to 25.4% (-890bps YoY, -400bps QoQ). Additionally, the margin-accretive industrials and healthcare segments delivered slower growth than the low-margin auto and durables businesses. EBITDA margin thus moderated 300bps YoY (-80bps QoQ) to 9.3% vs. 9.8% expected. Net working capital days inched up marginally to 83 days on a sequential basis.

**Strong order book; guidance maintained:** As of Dec'22, Syrma had outstanding orders worth Rs 21bn (vs. Rs 17bn in Q2FY23), with fresh intake of ~Rs 9bn from the industrial, consumer and auto verticals. Management continues to guide for revenue growth in line with the industry over the next couple of years and aims to achieve lower-double-digit margins on a sustainable basis. Exports (currently 35-40% of business) are guided to remained muted for the next two quarters but should be compensated for by domestic demand, thereby minimising the topline impact.

**Maintain BUY:** We believe Syrma has multiple growth levers in the form of a strong order book, timely capacity addition and traction in the auto, industrial and consumer verticals. Exports and working capital management are, however, key areas to watch in the near term. We adjust our FY23/FY24 EPS estimates by +7%/-3% to incorporate the Q3FY23 print as well as the shift in product mix. On rolling valuations forward to Dec'24, our TP increases to Rs 400 (earlier Rs 390), based on an unchanged 35x P/E multiple, a 15% discount to our EMS coverage comprising DIXON and AMBER. Maintain BUY.

#### Key changes

	Target	Rating			
Ticke	er/Price	SYRMA IN/Rs 265			
Mark	et cap	US\$ 566.7mn			
Free float		53%			
3M ADV		US\$ 1.6mn			
52wk high/low		Rs 343/Rs 248			
Promoter/FPI/DII		47%/5%/8%			

Source: NSE | Price as of 9 Feb 2023

#### Key financials

FY22A	FY23E	FY24E
12,666	18,945	25,319
1,260	1,783	2,502
765	1,170	1,606
4.3	6.6	9.1
4.3	-	-
13.8	11.0	9.9
61.2	40.0	29.1
37.1	26.2	18.7
16.7	53.0	37.3
	12,666 1,260 765 4.3 4.3 13.8 61.2 37.1	12,666 18,945   1,260 1,783   765 1,170   4.3 6.6   4.3 -   13.8 11.0   61.2 40.0   37.1 26.2

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance



Source: NSE





### Fig 1 – Quarterly performance

Particulars (Rs mn)	Q3FY23	Q3FY22	YoY (%)	Q2FY23	QoQ (%)	9MFY23	9MFY22	YoY (%)
Revenue	5,126	3,017	69.9	4,669	9.8	13,689	6,485	111.1
EBITDA	478	372	28.6	472	1.4	1,286	692	85.9
EBITDA Margin (%)	9.3	12.3	(300bps)	10.1	(80bps)	9.4	10.7	(130bps)
Depreciation	81	68	-	71	-	224	128	-
Interest	64	22	-	63	-	177	39	-
Other Income	118	17	-	79	-	221	42	-
PBT	451	298	51.1	417	8.0	1,106	566	95.4
Tax	108	96	-	128	-	304	194	-
Adjusted PAT	332	197	68.3	282	17.6	770	392	96.5
Exceptional item	-	-	-	-	-	-	-	-
Reported PAT	332	197	68.3	282	17.6	770	392	96.5
Adj. PAT Margin (%)	6.5	6.5	(10bps)	6.0	40bps	5.6	6.0	(40bps)
EPS (Rs)	1.9	1.1	69.7	1.6	18.2	4.6	2.1	115.7

Source: Company, BOBCAPS Research

### Fig 2 – Actual vs. Estimates

Particulars (Rs mn)	Actual	Estimates	Variance (%)
Revenue	5,126	4,107	24.8
EBITDA	478	403	18.8
EBITDA Margin (%)	9.3	9.8	(50bps)
Adj. PAT	332	233	42.6

Source: Company, BOBCAPS Research

# Earning call highlights

- Order book: Syrma closed Q3FY23 with an outstanding order book of Rs 21bn (vs. Rs 17bn in Q2), with fresh intake of ~Rs 9bn from the industrial, consumer and auto verticals. The company expects to complete orders worth Rs 8bn in the next 12 months.
- Guidance: Management continues to guide for revenue growth in line with the industry over the next couple of years and aims to achieve lower-double-digit margins on a sustainable basis.
- Exports: Exports, which act as a natural currency hedge and earn better margins for Syrma than domestic markets, were weighed down by inflationary pressures in western markets, especially Europe, in Q3. Management expects recovery after a couple of quarters. Currently, exports contribute 35-40% of total business and largely cater to the healthcare and industrial verticals.
- Healthcare: Syrma's healthcare vertical is largely export-oriented and is a solutionbased business that caters to lifestyle and life-caring products rather than lifesaving products. Lower discretionary spend amid the slowdown in western countries is, therefore, dampening growth in this segment.



- PLI: Syrma has attained the threshold capex and turnover limits in telecom, and is thus eligible for production-linked incentive (PLI) benefits. The company will file for these benefits in early-FY24 and expects to receive them toward the end of Q2FY24. Syrma hasn't initiated the investment capex cycle for white goods.
- Supply chain: Management indicated that semiconductor supply chain constraints have eased but that shortages still persist for products such as microcontrollers, which may take a couple more quarters to normalise. Fright cost has eased slightly.
- Business mix: The printed circuit board assembly (PCBA) vertical currently contributes 70-71% of revenue, box build forms 14-15% and electro-mechanical products make up the balance. The company has high capabilities in the box build business which match industry thresholds and typically manufactures products belonging to the industrial vertical that generate moderately higher margins than the PCBA business.
- Seasonality: Syrma caters to multiple industries and is thus well-diversified and not much impacted by seasonality. The monthly revenue run-rate has been rising (~Rs 1.2bn in Q1, ~Rs 1.4bn in Q2 and ~Rs 1.7bn in Q3), which implies strong structural growth. Additionally, the company is not materially dependent on government orders, which typically results in a better Q4 for a few of its peers. Thus, Q4 is likely to be a normal growth quarter for Syrma.
- Client concentration: The top-10 clients contribute ~46% of revenue which is lower than industry peers.
- Capex & Debt: The company has incurred capex worth Rs 350mn in Q3FY23 and aims to deploy another Rs 400mn-600mn in Q4. Further, it projects capex requirements of Rs 2bn-2.5bn for FY24. The debt position as of Dec'22 stands at Rs 3.3bn (Rs 2.4bn for working capital and Rs 0.9bn for long-term capex needs).



# Valuation methodology

We believe Syrma is set to outpace the industry given multiple growth levers in the form of a strong order book, timely capacity addition and traction in the auto, industrial and consumer verticals. Exports and working capital management are, however, key areas to watch in the near term. We adjust our FY23/FY24 EPS estimates by +7%/-3% to incorporate the Q3FY23 print as well as the shift in product mix towards the lower margin auto and consumer businesses.

On rolling valuations forward to Dec'24, our TP increases to Rs 400 (earlier Rs 390), based on an unchanged 35x P/E multiple – a 15% discount to our electronic manufacturing services (EMS) coverage comprising DIXON and AMBER. Our TP carries 52% upside potential; maintain BUY.

### Fig 3 – Revised estimates

Particulars (Rs mn)		New			Old		(	Change (%)	
Particulars (KS IIII)	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Sales	18,945	25,319	36,236	17,391	25,319	36,236	8.9	0.0	0.0
EBITDA	1,783	2,502	3,657	1,787	2,708	3,875	(0.2)	(7.6)	(5.6)
PAT	1,170	1,606	2,205	1,093	1,661	2,264	7.0	(3.3)	(2.6)
EPS	6.6	9.1	12.5	6.2	9.4	12.8	7.0	(3.3)	(2.6)
EBITDA Margin (%)	9.4	9.9	10.1	10.3	10.7	10.7	(90bps)	(80bps)	(60bps)

Source: Company, BOBCAPS Research

## Key risks

Key downside risks to our estimates are:

- below-expected revenue growth due to intensifying competition in the EMS space,
- inability to yield desired results from the added capacity, and
- margin compression from an adverse product mix and pricing pressure.

## Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Amber Enterprises	AMBER IN	0.8	1,887	2,100	HOLD
Blue Star	BLSTR IN	1.6	1,369	1,450	BUY
Crompton Greaves	CROMPTON IN	2.4	314	440	BUY
Dixon Technologies	DIXON IN	1.9	2,690	4,100	BUY
Havells India	HAVL IN	9.4	1,235	1,500	BUY
KEI Industries	KEII IN	1.8	1,640	1,900	BUY
Orient Electric	ORIENTEL IN	0.7	275	290	HOLD
Polycab India	POLYCAB IN	5.4	2,996	3,300	BUY
Syrma SGS	SYRMA IN	0.6	265	400	BUY
V-Guard Industries	VGRD IN	1.3	246	260	HOLD
Voltas	VOLT IN	3.3	825	950	HOLD

Source: BOBCAPS Research, NSE | Price as of 9 Feb 2023



# Financials

Income Statement	

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Total revenue	8,874	12,666	18,945	25,319	36,236
EBITDA	999	1,260	1,783	2,502	3,657
Depreciation	228	249	310	434	714
EBIT	772	1,010	1,473	2,068	2,943
Net interest inc./(exp.)	(71)	(80)	(220)	(247)	(338)
Other inc./(exp.)	169	177	310	326	342
Exceptional items	0	0	0	0	0
EBT	869	1,108	1,563	2,146	2,947
Income taxes	213	343	393	540	742
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	(1)	0	0	0	0
Reported net profit	655	765	1,170	1,606	2,205
Adjustments	0	0	0	0	0
Adjusted net profit	655	765	1,170	1,606	2,205

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Accounts payables	1,902	2,405	4,671	5,896	8,538
Other current liabilities	526	921	1,257	2,081	2,780
Provisions	0	0	0	0	0
Debt funds	925	1,942	3,380	4,939	6,752
Other liabilities	352	554	424	531	713
Equity capital	7	1,376	1,762	1,762	1,762
Reserves & surplus	5,355	4,344	13,838	15,092	16,900
Shareholders' fund	5,363	5,721	15,600	16,854	18,662
Total liab. and equities	9,068	11,542	25,333	30,300	37,445
Cash and cash eq.	1,092	732	9,834	7,960	7,239
Accounts receivables	2,084	2,722	3,633	5,203	7,148
Inventories	1,789	2,913	5,035	6,590	9,431
Other current assets	467	645	1,246	1,526	2,184
Investments	31	47	70	94	135
Net fixed assets	3,304	3,793	4,483	7,549	9,334
CWIP	0	391	584	781	1,117
Intangible assets	0	0	0	0	0
Deferred tax assets, net	0	0	0	0	0
Other assets	301	299	448	598	856
Total assets	9,068	11,542	25,333	30,300	37,445

#### Cash Flows

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Cash flow from operations	371	(126)	449	684	815
Capital expenditures	(187)	(901)	(1,000)	(3,500)	(2,500)
Change in investments	(50)	43	(23)	(24)	(41)
Other investing cash flows	(886)	4,849	(471)	(241)	(413)
Cash flow from investing	(1,123)	3,992	(1,495)	(3,765)	(2,953)
Equities issued/Others	1,079	2,715	386	0	0
Debt raised/repaid	(75)	1,021	1,438	1,559	1,813
Interest expenses	0	0	0	0	0
Dividends paid	(288)	85	8,324	(352)	(397)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	716	3,821	10,147	1,206	1,417
Chg in cash & cash eq.	(36)	7,687	9,102	(1,874)	(721)
Closing cash & cash eq.	1,092	732	9,834	7,960	7,239

Per Share Y/E 31 Mar (Rs)	FY21A	FY22A	FY23E	FY24E	FY25E
Reported EPS	3.7	4.3	6.6	9.1	12.5
Adjusted EPS	3.7	4.3	6.6	9.1	12.5
Dividend per share	0.0	0.0	0.0	2.0	2.3
Book value per share	30.4	32.5	88.5	95.6	105.9
	00.4	02.0	00.0	50.0	100.0
Valuations Ratios					
Y/E 31 Mar (x)	FY21A	FY22A	FY23E	FY24E	FY25E
EV/Sales	5.3	3.7	2.5	1.8	1.3
EV/EBITDA	46.8	37.1	26.2	18.7	12.8
Adjusted P/E	71.4	61.2	40.0	29.1	21.2
P/BV	8.7	8.2	3.0	2.8	2.5
DuPont Analysis					
Y/E 31 Mar (%)	FY21A	FY22A	FY23E	FY24E	FY25E
Tax burden (Net profit/PBT)	75.4	69.0	74.8	74.8	74.8
Interest burden (PBT/EBIT)	112.6	109.6	106.1	103.8	100.1
EBIT margin (EBIT/Revenue)	8.7	8.0	7.8	8.2	8.1
Asset turnover (Rev./Avg TA)	2.7	3.3	4.2	3.4	3.9
Leverage (Avg TA/Avg Equity)	0.7	0.7	0.4	0.5	0.5
Adjusted ROAE	13.2	13.8	11.0	9.9	12.4
Ratio Analysis					
Y/E 31 Mar	FY21A	FY22A	FY23E	FY24E	FY25E
YoY growth (%)					
Revenue	2.5	42.7	49.6	33.6	43.1
EBITDA	(26.8)	26.1	41.5	40.4	46.2
Adjusted EPS	(32.5)	16.7	53.0	37.3	37.3
Profitability & Return ratios (%)					
EBITDA margin	11.3	9.9	9.4	9.9	10.1
EBIT margin	8.7	8.0	7.8	8.2	8.1
Adjusted profit margin	7.4	6.0	6.2	6.3	6.1
Adjusted ROAE	13.2	13.8	11.0	9.9	12.4
ROCE	14.4	13.4	9.9	8.7	10.4
Working capital days (days)					
Receivables	86	78	70	75	72
Inventory	74	84	97	95	95
intentery		69	90	85	86
Payables	78	69			
•	78	09			
Payables	78 2.5	3.1	3.8	3.5	3.6
Payables Ratios (x)					
Payables Ratios (x) Gross asset turnover	2.5	3.1	3.8	3.5	3.6

Adjusted debt/equity Source: Company, BOBCAPS Research | Note: TA = Total Assets

0.2

0.3

0.2 0.3

0.4



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

# Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### Ratings and Target Price (3-year history): SYRMA SGS (SYRMA IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

## SYRMA SGS



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company, except for Research Analyst Vinod Chari having 875 shares of Voltas (VOLT IN). BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research

report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions. BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquires, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "**MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.